RESUMEN
AIMS: Teleconsultation has been widely utilised during the COVID-19 pandemic. It allows clinicians to provide healthcare social distance restrictions. This study investigates its safety and limitations in different specialties and the possibility of incorporating telemedicine into future practice. METHODS: This was a qualitative study of 151 hospital-based specialists in New Zealand. An electronic questionnaire was sent via email addresses. These included participants' demography and their experience of using teleconsultation during the pandemic. The safety and suitability of teleconsultation were assessed with time efficiency, data security concerns, missed clinical information and specialist's ability to examine patients. RESULTS: This study found that 92.7% of hospital-based specialists used teleconsultation during the pandemic. More specialists reported the efficiency was similar or greater with teleconsultation and most patients could be seen via teleconsultation appointments. Limitations of these were due to poor physical examination and poor non-verbal cues sensing. There is a general preference for physical consultation. CONCLUSION: Teleconsultation is used widely across many specialties during the pandemic. Despite limitations identified with teleconsultations and preference for physical consultation, doctors are prepared to provide teleconsultations in the future beyond the pandemic. In appropriately selected patients, especially in non-procedural specialties, teleconsultation will have an increasing role in healthcare.
Asunto(s)
COVID-19 , Consulta Remota , Telemedicina , COVID-19/epidemiología , Hospitales , Humanos , Nueva Zelanda/epidemiología , PandemiasRESUMEN
Lyme disease, which is primarily caused by infection with the bacterium Borrelia burgdorferi in the United States or other Borrelia species internationally, presents an ongoing challenge for diagnostics. Serological testing is the primary means of diagnosis but testing approaches differ widely, with varying degrees of sensitivity and specificity. Moreover, there is currently no reliable test to determine disease resolution following treatment. A distinct challenge in Lyme disease diagnostics is the variable patterns of human immune response to a plurality of antigens presented by Borrelia spp. during the infection. Thus, multiplexed testing approaches that capture these patterns and detect serological response against multiple antigens may be the key to prompt, accurate Lyme disease diagnosis. In this review, current state-of-the-art multiplexed diagnostic approaches are presented and compared with respect to their diagnostic accuracy and their potential for monitoring response to treatment.
Asunto(s)
Enfermedad de Lyme/diagnóstico , Enfermedad de Lyme/inmunología , Antígenos Bacterianos/inmunología , Borrelia burgdorferi/inmunología , Humanos , Inmunidad/inmunología , Sensibilidad y Especificidad , Pruebas Serológicas/métodosRESUMEN
Lyme disease (LD) diagnosis using the current two-tier algorithm is constrained by low sensitivity for early-stage infection and ambiguity in determining treatment response. We recently developed a protein microarray biochip that measures diagnostic serum antibody targets using grating-coupled fluorescent plasmonics (GC-FP) technology. This strategy requires microliters of blood serum to enable multiplexed biomarker screening on a compact surface and generates quantitative results that can be further processed for diagnostic scoring. The GC-FP biochip was used to detect serum antibodies in patients with active and convalescent LD, as well as various negative controls. We hypothesized that the quantitative, high-sensitivity attributes of the GC-FP approach permit: 1) screening of antibody targets predictive for LD status, and 2) development a diagnostic algorithm that is more sensitive, specific, and informative than the standard ELISA and Western blot assays. Notably, our findings led to a diagnostic algorithm that may be more sensitive than the current standard for detecting early LD, while maintaining 100% specificity. We further show that analysis of relative antibody levels to predict disease status, such as in acute and convalescent stages of infection, is possible with a highly sensitive and quantitative platform like GC-FP. The results from this study add to the urgent conversation regarding better diagnostic strategies and more effective treatment for patients affected by tick-borne disease.
Asunto(s)
Anticuerpos Antibacterianos/sangre , Fluorescencia , Dispositivos Laboratorio en un Chip , Enfermedad de Lyme/sangre , Enfermedad de Lyme/diagnóstico , Tamizaje Masivo/instrumentación , Humanos , Enfermedad de Lyme/inmunología , Factores de TiempoRESUMEN
Purpose: Delays in diagnosis and treatment are regularly discussed as potential poor prognostic factors for adolescent and young adult (AYA) cancer patients. We aimed to determine whether AYA cancer patients (15-24 years of age) in the South Island of New Zealand had longer times to diagnosis and treatment than pediatric (<15 years) and adult patients (>24 years) with the same diagnosis. Methods: A retrospective review of medical records was undertaken for 201 recently diagnosed sarcoma, Hodgkin lymphoma (HL), and non-Hodgkin lymphoma (NHL) patients in the South Island. An age stratified analysis was undertaken with a number of intervals related to the time to diagnosis (TTD) and total interval (TI) being determined. Results: Overall, the AYA group's TTD and TI was longer than the pediatric group, but shorter than the adult group. No age-based differences in patient interval (PI) were identified. AYA and adult sarcoma patients had longer TTD and TI than pediatric sarcoma. AYA and pediatric NHL patients had a shorter TTD and TI than adult NHL. No significant age-related interval differences were found in the HL group. Conclusions: AYA patients had a longer TTD and TI when compared with the pediatric group, but not when compared with the adult group. The impact of established AYA barriers to presentation are questioned, given no age-based differences in PI were found. The influence of tumor biology and cancer service delivery is an important consideration. Improved applicability of this type of research will be enabled by international collaboration.
Asunto(s)
Continuidad de la Atención al Paciente/estadística & datos numéricos , Accesibilidad a los Servicios de Salud/estadística & datos numéricos , Enfermedad de Hodgkin/terapia , Linfoma no Hodgkin/terapia , Sarcoma/terapia , Tiempo de Tratamiento/estadística & datos numéricos , Adolescente , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Niño , Preescolar , Femenino , Estudios de Seguimiento , Humanos , Lactante , Recién Nacido , Masculino , Persona de Mediana Edad , Nueva Zelanda , Pronóstico , Estudios Retrospectivos , Adulto JovenRESUMEN
Lyme disease (LD) is the most common tick-borne disease in the Northern Hemisphere. As the most prevalent vector-borne disease in the USA, LD affects 300,000 human cases each year. LD is caused by inoculation of the bacterial spirochete, Borrelia burgdorferi sensu lato, from an infected tick. If not treated quickly and completely, the bacteria disseminate from the tick's biting site into multiple organs including the joints, heart, and brain. Thus, the best outcome from medical intervention can be expected with early detection and treatment with antibiotics, prior to multi-organ dissemination. In the absence of a characteristic rash, LD is diagnosed using serological testing involving enzyme-linked immunosorbent assay (ELISA) followed by western blotting, which is collectively known as the two-tier algorithm. These assays detect host antibodies against the bacteria, but are hampered by low sensitivity, which can miss early LD cases. This review discusses the application of some current assays for diagnosing LD clinically, thus providing a foundation for exploring newer techniques being developed in the laboratory for more sensitive detection of early LD.
Asunto(s)
Enfermedad de Lyme/diagnóstico , Técnicas de Diagnóstico Molecular/métodos , Borrelia burgdorferi/genética , Borrelia burgdorferi/inmunología , Ensayo de Inmunoadsorción Enzimática/métodos , Humanos , Enfermedad de Lyme/sangre , Reacción en Cadena de la Polimerasa/métodos , Pruebas Serológicas/métodosRESUMEN
Manganese-containing fungicides like Mancozeb have been associated with neurodegenerative conditions like Parkinson's disease. We examined the behavioral damage and differential neuronal vulnerability resulting from Mancozeb exposure using Caenorhabditis elegans, an important mid-trophic level soil organism that is also a powerful model for studying mechanisms of environmental pollutant-induced neurodegenerative disease. The dopamine-mediated swim to crawl locomotory transition behavior is exquisitely vulnerable to Mancozeb, with functional impairment preceding markers of neuronal structural damage. The damage is partially rescued in mutants lacking the divalent metal transporter, SMF-1, demonstrating that some, but not all, of the damage is mediated by manganese. Increasing concentrations of Mancozeb recruit additional behavioral dysfunction, notably serotonin-mediated egg-laying behavior, but without evident serotonergic neuronal structural damage. Thus, measurements of behavioral dysfunction are a sensitive early marker of fungicide toxicity that could be exploited to examine further mechanisms of neuron damage and possible therapeutic interventions. These results also provide important insight into the consequences of fungicide use on the ecological behavior of nematodes.